This study evaluates the outcomes of BeGraft stents used as bridging stents during fenestrated endovascular aortic aneurysms repair. To date, none of the balloon expandable covered stents which are currently commercially available in Europe have been specifically designed and evaluated for that purpose.
INTRODUCTION
Fenestrated endovascular aortic repair (FEVAR) is a validated option for treating complex aortic aneurysms. 1, 2 This challenging endovascular procedure may be associated with early or late complications such as target vessel occlusion. 3 Target vessels patency rates at 1 year follow-up of 92%e98% have been reported in the literature. 4e7 Reinterventions after FEVAR are frequent, ranging from 7.6% to 26.2%; they are often performed to treat bridging stent related type 3 endoleaks. Bridging stents are associated with specific complications such as fracture, occlusion and type 3 endoleaks during follow-up. Choosing the adequate bridging stent is therefore of paramount importance to ensure the technical success and durability of FEVAR. Clinical studies have evaluated covered and uncovered stents 4, 12 implanted during FEVAR; however, there is currently a general consensus in favour of the liberal use of covered stents, which are associated with a 2.5% occlusion rate compared with the occlusion rate of 10% for uncovered stents described by Mohabbat et al. 13 None of the balloon expandable covered stents which are currently commercially available have been specifically designed and tested as bridging stents for FEVAR. To date, the following covered stents have been used as bridging stents during FEVAR: JOSTENT (Abbott Laboratories, Abbott Park, Illinois, USA), Advanta V12 (Atrium Medical, Hudson, New Hampshire, USA), Lifestream (Bard, Tempe, Arizona, USA), and BeGraft (BentleyInnoMed, Hechingen, Germany). 14, 15 All these stents are manufactured with expanded polytetrafluoroethylene (ePTFE) fabric and a stainless steel stent, except the BeGraft, which is based on a cobalt chromium stent. Compared with the first generation of the BeGraft, the second generation was modified (among other changes) by increasing the thickness of the ePTFE covering (from 100 mm to 200 mm) and the width of the stent connectors (by approx. 20%). The bench test results provided by the manufacturer revealed significantly improved sealing properties and radial force; it was considered that these new features made this new platform suitable for use as a bridging stent during FEVAR. This is an off label use of this stent. This second generation has the same profile characteristics as the first (6Fr compatibility up to 8 mm in diameter) and is therefore still compatible with preloaded delivery systems to the renal arteries. In addition, it is the only available stent manufactured in large diameters (8e10 mm) and short lengths (27 or 28 mm). For these reasons, this second generation stent graft was used routinely during FEVAR when renal arteries required bridging stents > 6 mm in diameter or > 22 mm in length, or when visceral arteries required bridging stents > 7 mm in diameter and < 38 mm in length.
In this prospective study, the outcomes of the first consecutive 101 BeGraft stent grafts used as bridging stents during FEVAR for complex aneurysm repairs were evaluated.
MATERIAL AND METHODS

Study population
During the study period, all consecutive patients treated at the study centre with second generation BeGraft stent grafts during fenestrated endograft repair (FEVAR) for complex aneurysm were prospectively included. Indication for repair was maximum aortic diameter > 55 mm or rapid growth (>10 mm in 12 months). BeGraft stent grafts were used as bridging stents to connect fenestrations to target vessels (renal and visceral arteries) when renal arteries required bridging stents > 6 mm in diameter or > 22 mm in length, or when visceral arteries required bridging stents > 7 mm in diameter and < 38 mm in length (inclusion criteria). Standard bridging stents were used in target vessels with anatomies outside the inclusion criteria. These second generation BeGraft stent grafts became available at the study centre in October 2015, which is the starting date for enrolment in the study. The goal was to evaluate the 1 year outcomes of the first 100 BeGraft stent grafts implanted. Patients undergoing FEVAR without BeGraft stent grafts during the study period were not included. During follow-up, adverse events were collected according to reporting standards. 17 Renal insufficiency was defined as a GFR estimated with MDRD 60 mL/min and renal impairment as a post-operative decrease in GFR of more than 20% compared with the pre-operative GFR. Computed tomography (CT) scans were performed during the first post-operative month and at 1 year. Doppler ultrasound was performed before discharge (mostly contrast enhanced exams), at 6 months, and at 1 year.
Follow-up was defined as early during the first 30 postoperative days, and late thereafter.
The study was approved by the research ethics committee and signed informed consent was obtained from all patients.
Fenestrated endografts
All fenestrated endografts were custom made and manufactured by Cook Medical (Bloomington, IN, USA). They were delivered through 20 to 22Fr delivery sheaths. Most renal fenestrations were preloaded with a catheter. Technical details of the deployment sequence have been described previously. 18 The procedures were always performed under fusion imaging guidance (Innova Vision, GE Healthcare, Chalfont St Giles, UK). At the end of the procedure, a completion cone beam CT (CBCT) was always performed (with contrast when eGFR was > 60 mL/min). Procedures were all performed under general anaesthesia in a hybrid room (Discovery IGS 730, GE Healthcare, Chalfont, UK). Patients with type 1, 2, or 3 TAAA underwent a standardised protocol for spinal cord ischaemia prevention. 19 Single antiplatelet therapy was started before the procedure, was not discontinued at the time of the procedure, and continued thereafter. During the procedure, to obtain a target ACT > 250 s, 100 units/kg of heparin were injected intravenously.
Pre-operative planning of bridging stents
All target arteries were analysed on the pre-operative CT scan using a 3D workstation. A centreline was generated for each target artery and corrected manually when required. The curved planar reconstruction allowed analysis of the diameter of the target artery at the intended sealing zone, and the distance from its origin to the first division branch. Using both parameters, the bridging stent's diameter and length were determined pre-operatively, with no oversizing of the stent diameter, and no coverage of division branches of the target vessel. Bridging stents implanted during the study period were second generation BeGraft stent grafts, Advanta V12 (Atrium Medical, Hudson, New Hampshire, USA) or Lifestream (Bard, Tempe, Arizona, USA).
Bridging stent implantation
The bridging stents are positioned so that 3e4 mm protrudes into the aortic lumen. The balloon of the bridging stent is then inflated to 10 bar. The protruding segments are flared with 9 mm diameter e 20 mm length balloons (Mustang, Boston Scientific, Marlborough, MA, USA) in the renal stents (implanted through 6 mm diameter fenestrations), and a 10 mm diameter e 20 mm length balloon in the visceral stents (implanted through 8 mm fenestrations). The proximal marker of the flaring balloon is advanced to the level of the fenestration markers and the balloon is inflated to 10 bar. Positive pressure was applied on the shaft of the balloon to position it horizontal to obtain a 360 flair of the aortic portion of the bridging stent.
Statistical analysis
Continuous variables are expressed as median with interquartile ranges (Q1-Q3). Categorical variables are presented as percentages. All statistical analyses were conducted with GraphPad Prism 6.0 (GraphPad software Inc, La Jolla, CA, USA). 
RESULTS
Pre-operative demographics
Procedure data
The fenestrated endografts had two (1/39), three (7/39), four (28/39), or five fenestrations (3/39). Delivery systems with preloaded renal catheters were used in 37/39 patients (92.3%). Technical success was achieved in all cases. Median duration of the procedure was 200 min (180e215) with a median fluoroscopy time of 48 min (39.0e72.5) and a median DAP of 71.2 Gy cm 2 (45.9e101.0). Median volume of contrast injected was 100 mL (77.5e122.5) ( Table 2 ). The distal component was a bifurcated endograft in 28 patients and a tubular infrarenal endograft in 11 patients. An iliac branched graft (ZBIS, Cook Medical) was also implanted in four patients. A proximal thoracic extension was required in six patients. An access conduit was used in three patients.
BeGraft stent grafts as bridging stents
Among the 150 fenestrations, 97 (97/150, 64.7%) were bridged with BeGraft stent grafts. One fenestration was deliberately not stented because of the intra-operative diagnosis of coeliac trunk occlusion.
Eight patients (8/39, 20.5%) were treated by BeGraft stent grafts for all fenestrations. A total of 101 BeGraft stent grafts were successfully deployed. Two renal fenestrations in patients with chronic dissections required two and three stents, respectively. In one case, because of the length of the false lumen to bridge, and in the second case, the target renal artery was dissected and long coverage was required to obtain a seal distal to the dissection.
Among the 101 BeGraft stent grafts delivered, 55 were implanted in visceral arteries (22 in coeliac trunks, 31 in the superior mesenteric artery (SMA) and 2 in a hepatic or splenic artery), and 46 in renal arteries (24 right and 22 left) ( Table 3 ). The renal artery diameter was 5, 6, 7, and 8 mm in 9, 7, 26, and 4 patients, respectively.
Visceral arteries were exclusively stented with 9 and 10 mm diameter BeGraft stent grafts. Short lengths (18 mm) were only required in two renal arteries. Long length (37 mm or 38 mm) stents were required in six target vessels, including two renal arteries. All other target vessels were stented with 23 or 27e28 mm long BeGraft stent grafts. Details are presented in Table 3 .
Additional intra-operative procedures on bridging stents
During deployment, misplacement of bridging stents was observed in four target arteries. None were BeGraft stent grafts (Table 4) . In those cases, the intra-aortic portion of the bridging stent was too short. All were treated by additional implantation of a covered stent. One patient had a calcified stenosis at the origin of the SMA. The initial bridging stent had a residual stenosis at the level of the stenosis. It was successfully relined with a BeGraft.
Selective angiography or cone beam CT revealed four type 3 endoleaks secondary to misplacement of the bridging stents, none with the BeGraft.
Nitinol self-expanding stents were implanted to treat acute angulation between the end of the bridging stent and its target artery in four patients (Table 4) .
In two cases, a kink of the intra-aortic portion of the bridging stent was detected on completion cone beam CT (CBCT). The kinks were probably secondary to damage of the bridging stent caused by the delivery system of the bifurcated component inserted after bridging stent deployment. One was a BeGraft stent graft that was successfully catheterised antegradely. The other kinked bridging stent was catheterised retrogradely during a translumbar approach. An additional covered stent (BeGraft) was deployed to treat the kink. 20 
Early follow-up
Median ICU and hospitalisation length of stay were, respectively, 1 day (1e4) and 10 days (8e14.5) ( Table 5) . No early mortality occurred. Adverse events and secondary interventions occurred in seven patients (7/39, 17.9%) secondary to: -Cholesterol emboli syndrome from a "shaggy" aorta requiring transient post-operative dialysis and secondary interventions on post-operative days 1 and 11 for acute limb ischaemia and acute bowel ischaemia. -Acute renal stent thrombosis and renal haematoma leading to haemodynamic instability and spinal cord ischaemia. This patient required a secondary intervention (renal artery recanalisation) and post-operative dialysis.
-Bowel ischaemia following an SMA dissection probably caused by a wire injury; bowel resection and SMA stenting with a self-expanding nitinol stent were performed. -Acute mesenteric haemorrhage on post-operative day 7 requiring emergency laparotomy. Spinal cord ischaemia was diagnosed after the laparotomy. -Renal haematoma requiring supra-selective renal embolisation. -Anastomotic stenosis of an access bypass; endovascular treatment was performed on post-operative day 12. -Iliac thrombosis; a femoro-femoral bypass was performed on post-operative day 12.
BeGraft stent graft patency was 99% (100/101). One renal stent thrombosed immediately post-operatively as described above. The respective CT scan showed a dissection of the renal artery distal to the stent graft, but complementary stenting was unsuccessful to recover patency of the renal artery. An acute angulation distal to the contralateral artery stent required additional preventive nitinol stenting. Among all, two post-operative dialyses were required (2/39, 5.1%), of which one was transient. No other renal impairment was observed.
On early post-operative imaging, four type 2 endoleaks were observed but no type 1 or type 3 endoleaks.
Late follow-up
Median follow-up was 13 months (11e15). Six type 2 endoleaks were shown on follow-up and one endoleak from the distal end of a BeGraft stent graft (type Ib). One sac enlargement (1/39, 2.6%) was seen in a patient with a type 2 endoleak. In the other 38 patients, the aneurysm sac had shrunk (18/39, 46.1%) or was stable (20/39, 51.3%) at 1 year (Table 5) .
On follow-up, two patients required dialysis (2/39, 5.1%): the patient with pre-operative definitive dialysis, and the patient with bilateral renal occlusion following the procedure. No other renal impairment was observed.
BeGraft stent graft patency during follow-up was 98%. The patient with a post-operative renal occlusion had a contralateral renal BeGraft stent graft occlusion on CT scan 2 months after the procedure. All other BeGraft stent grafts (99/101, 98%) remained patent.
Secondary interventions during follow-up were performed in five patients (5/39, 12.8%). The first patient was the one with the cholesterol emboli syndrome who required a redo laparotomy. The second had a type 2 endoleak with aneurysm sac growth that required selective IMA embolisation at 5 months. The third patient had haemostasis disorders. At 4 months he presented with an access haematoma which required secondary intervention, without any active bleeding observed. The patient who required intestinal resection was restored to normal bowel circulation at 7 months. The type Ib endoleak was not associated with aneurysmal growth, but additional angioplasty and stenting were performed at 16 month follow-up.
The survival rate at the last follow-up was 87.2% (34/39). The patient with renal artery thrombosis and paraplegia suffered from severe malnutrition and died at 3 months. The patient with cholesterol emboli syndrome died at 5 months from a peritoneal infection. Three other patients died from stroke, haematopathy, and metastatic bowel cancer that was not diagnosed pre-operatively, respectively, 2, 5, and 4 months after the initial procedure.
DISCUSSION
This single centre prospective study series reports favourable one year outcomes of 101 s generation BeGraft stent grafts used as bridging stents during FEVAR. To date, no stent has been specifically developed for this application. Oderich et al. advocate the need to focus on bridging stent technology to reduce occlusions, type III endoleaks, and reintervention rates. 9 Success and durability of FEVAR are closely linked to the effectiveness of the bridging stent. In the literature, 1 year target vessel patency rates after complex endovascular repairs range from 92% to 98%.
4e7 It is not easy to analyse the literature as a mix of complex abdominal AAA and TAAA are reported. Results with BeGraft stent grafts compare favourably with these rates with a one year 98% patency rate in the present study. The 2% renal occlusion rate observed in this study was similar to the 2.3% occlusion rate reported in the multicentre study on F/BEVAR published by Martin Gonzalez et al. 21 In the present series, two renal stents occluded in the same patient: one following a dissection distal to the stent and the contralateral one following kidney sub capsular haematoma. Both were 5 mm diameter stents. No anomalies of these stents were observed during the early secondary procedure or on the post-operative CT scan. The small diameter of the renal arteries in this patient is probably not the root cause of the occlusions; it is usually not recommended to design fenestrations for target vessels that are less than 4 mm in diameter as bridging stents implanted in such vessels tend to occlude. 13 Stent fracture can be associated with target artery occlusion following FEVAR. 4 At one year follow-up, no stent fracture with the BeGraft was observed on post-operative imaging. Type 3 endoleaks, described by Mastracci et al. as endoleaks from bridging stent disconnection to the fenestration or disconnection between two bridging stents, 5 are reported to be the major cause of re-intervention following complex endovascular repair. 22 In practice with this new generation stent, flaring is very efficient, and the present authors have not observed any type 3 endoleaks. The aortic portion of the stent, which is very well visualised (cobalt-chromium alloy offers an opacity that allows accurate positioning during deployment) during the procedure, conformed very well to the 10 mm diameter flaring balloon, and provided a durable seal at the connexion with the nitinol reinforced fenestrations. In the present study, there was no evidence that the stent design (PTFE outside and metallic struts inside) was associated with more difficult tracking, or excessive friction, compared with experience with other bridging stents. The implantation technique was similar.
BeGraft stent grafts in this series were implanted in visceral (54.9%) as well as in renal arteries (45.1%). In the literature, renal arteries are associated with a higher rate of secondary interventions compared with visceral arteries. 15 Following type II and type III TAAA endovascular repair, visceral artery primary patency rates (96% for coeliac trunks, 95% for SMA) were higher than those of renal arteries at 36 months (94% and 92% for right and left renal artery, respectively). 8 Similarly, secondary procedures on BeGraft stent grafts were only required to treat renal artery issues: one early re-intervention for a renal artery dissection and a late one to treat a type Ib endoleak. The latter resulted from underestimation of the renal artery diameter and was responsible for the only late secondary procedure (percutaneous balloon angioplasty) during follow-up performed on BeGraft stent grafts. No secondary intervention was required on visceral arteries.
When performing FEVAR, delivery systems with preloaded renal catheters are routinely used, which allows for renal access and stenting through 6Fr sheaths from the same side as the endograft delivery. 18 They provide a very stable platform to catheterise challenging renal arteries (i.e. downward looking with ostial stenosis) and only require one access iliac vessel compatible with a 20Fr or 22Fr delivery system; access to the visceral arteries can be achieved from the contralateral side through a 16Fr sheath or directly advancing two separate 6 or 7Fr sheaths. Delivery systems with preloaded renal catheters are not yet widely available and thus not common to many FEVAR operators.
Renal impairment is a concern after FEVAR as it is the most frequent complication. 23 In the present study, only one permanent dialysis (2.6%) and one transient dialysis (2.6%) were required. These results are comparable with those of a recent study on F/BEVAR with a 5% rate of postoperative dialysis. 6 Following FEVAR, Martin Gonzalez et al. reported that 37% of patients experience a decrease in eGFR. 21 No renal impairment other than the permanent dialysis was observed in the present study. The patient with transient dialysis had recovered to his baseline eGFR at 4 month follow-up.
CBCT (Discovery IGS 730, GE Healthcare) is systematically performed at the end of the procedure. CBCT offers a 3D imaging assessment which is more accurate than a 2D completion angiogram. 24 As described above, CBCT picked up two bridging stent issues which could be fixed during the same procedure, thus limiting the need for secondary procedures and enhancing the technical success rate.
Bridging stent patency was carefully followed using Doppler ultrasound, contrast enhanced where available. Contrast enhanced doppler ultrasound is as accurate as CT scan in detecting FEVAR issues. 25 This follow-up technique lowers radiation dose and the volume of iodinated contrast while revealing early stent issues. In this study, no stent stenosis was observed with BeGraft stent grafts. One type 1b endoleak was diagnosed using contrast enhanced Doppler ultrasound and treated. This methodical follow-up is mandatory as attempts to recanalise occluded stents are usually unsuccessful. 5 
CONCLUSION
Second generation BeGraft stent grafts can safely be used as bridging stents in FEVAR and are associated with favourable outcomes at 1 year follow-up. Long-term followup is required to confirm these encouraging results.
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